These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29787575)

  • 1. Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms.
    Urrutia VC; Faigle R; Zeiler SR; Marsh EB; Bahouth M; Cerdan Trevino M; Dearborn J; Leigh R; Rice S; Lane K; Saheed M; Hill P; Llinas RH
    PLoS One; 2018; 13(5):e0197714. PubMed ID: 29787575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.
    Lewandowski CA; Frankel M; Tomsick TA; Broderick J; Frey J; Clark W; Starkman S; Grotta J; Spilker J; Khoury J; Brott T
    Stroke; 1999 Dec; 30(12):2598-605. PubMed ID: 10582984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E; Minematsu K; Nakagawara J; Yamaguchi T;
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
    Uchino K; Alexandrov AV; Garami Z; El-Mitwalli A; Morgenstern LB; Grotta JC
    Cerebrovasc Dis; 2005; 19(4):260-6. PubMed ID: 15731557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Primary Imaging Modality-Computed Tomography or Magnetic Resonance Imaging-Influence Stroke Physicians' Certainty on Whether or Not to Give Thrombolysis to Randomized Acute Stroke Patients?
    Hansen CK; Christensen A; Rodgers H; Havsteen I; Kruuse C; Christensen H
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):926-935. PubMed ID: 29198901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset.
    Balogun IO; Brown A; Bertoni M; Webb T; Hargroves D; Pullicino P
    J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):1843-50. PubMed ID: 27132489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of Thrombolysis in a Developing Country: Characteristics and Outcomes in Peru.
    Abanto C; Valencia A; Calle P; Barrientos D; Flores N; Novoa M; Ecos RL; Ramirez JA; Ulrich AK; Zunt JR; Tirschwell DL; Wahlster S
    J Stroke Cerebrovasc Dis; 2020 Jul; 29(7):104819. PubMed ID: 32307317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
    Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
    Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRUST-tPA trial: Telemedicine for remote collaboration with urgentists for stroke-tPA treatment.
    Mazighi M; Meseguer E; Labreuche J; Miroux P; Le Gall C; Roy P; Tubach F; Amarenco P
    J Telemed Telecare; 2017 Jan; 23(1):174-180. PubMed ID: 26656722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic therapy for wake-up stroke: A systematic review and meta-analysis.
    Mac Grory B; Saldanha IJ; Mistry EA; Stretz C; Poli S; Sykora M; Kellert L; Feil K; Shah S; McTaggart R; Riebau D; Yaghi S; Gaines K; Xian Y; Feng W; Schrag M
    Eur J Neurol; 2021 Jun; 28(6):2006-2016. PubMed ID: 33772987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.